Just recently, Schram et al. demonstrated in a non-randomized tumor agnostic phase IIb basket study (n = 200) that patients with locally advanced or mPDAC (n = 16) displaying a germline or somatic mutation in BRCA1, BRCA2, or ATM and treated with the anti-PD-L1 Ab avelumab combined with the PARP inhibitor talazoparib yielded an ORR of 12.5% [63]. This evidence concerns the gene CD274 and neoplasm.